Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaine SCHEMBL6140458 | 0.83 | TSHR (0.45) | TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL907529 | 0.80 | TSHR (0.34) | TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL22686151 | 0.79 | TSHR (0.40) | TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL7974165 | 0.79 | TSHR (0.35) | TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL8807531 | 0.72 | BBOX1 (0.40) | TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL9330112 | 0.72 | TSHR (0.32) | TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL28548907 | 0.71 | TSHR (0.36) | TSHRALDH1A1 | |
| Betaine SCHEMBL23795787 | 0.68 | TSHR (0.33) | TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL640365 | 0.67 | — | — | |
| Methacrylic Acid SCHEMBL29048808 | 0.67 | MAPT (0.39) | TSHRALDH1A1LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208460-B2 | Single-arm type I and type II receptor fusion proteins and uses thereof | ACCELERON PHARMA INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200055920-A1 | SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF | ACCELERON PHARMA INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055920-A1 | SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF | ALK, ACVR2A, TGFBR2 | TSHR 1303/4885ALDH1A1 3779/4885LMNA 2366/4885 |
| US-11208460-B2 | Single-arm type I and type II receptor fusion proteins and uses thereof | ALK, ACVR2A, TGFBR2 | TSHR 1303/4885ALDH1A1 3779/4885LMNA 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.